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Adverse Effects of Medications on 
Periodontal Tissues
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Abstract
Periodontal tissue is susceptible to a range of adverse effects of several medications 
used in daily medical practice. Phenytoin, cyclosporine, and calcium-channel blockers 
are the most commonly used drugs related to gingival disease. Several other medica-
tions can also have an adverse effect on the periodontium, especially in the presence of 
compromised oral hygiene. These medications act on periodontal tissues by trigger-
ing the inflammatory pathways involved in the pathogenesis of periodontal disease 
or by potentially compromising the management of patients with these conditions. 
Gingival overgrowth is probably the mostly widely recognized and investigated type 
of adverse drug reaction in the periodontal tissues. Since many patients are on such 
medications, dental practitioner should take a thorough medical history and be aware 
of medication-related problems and their potential effects on diagnosis and treatment 
planning. The chapter reviews the commonly prescribed medications that can affect 
the periodontium either in its healthy or inflamed condition.
Keywords: adverse effects, calcium channel blockers, gingival overgrowth, 
hypertension, anticonvulsants, immunosuppressants
1. Introduction
Medications are chemical substances used to treat, cure, prevent, or diagnose a 
disease or to promote well-being. An adverse drug reaction is defined by WHO as 
a response to a drug which is noxious and unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis, therapy of diseases or for 
the modification of physiological function. Several medications can cause adverse 
effects in the periodontium. The most common are the gingival enlargement, 
inflammation, pigmentations, gingival bleeding and osteonecrosis [1]. Gingival 
overgrowth (GO) or enlargement is a condition is characterized by an increase 
in the size of gingiva subsequent to the increase in extracellular tissue volume. 
Gingival overgrowth is a side effect of several medications used by patients have 
the capability to cause adverse effects in the oral cavity and periodontal tissues [2]. 
Though many medications have marked effects on the periodontal tissues and these 
adverse reactions are well documented, many have been described only as isolated 
case series or reports [2]. It is important for the clinician to obtain a complete record 
of the medications the patient takes, including prescription drugs and over-the-
counter drugs. This will help the  clinician to diagnose and manage the adverse 
effects in the periodontal tissues.
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2. Drug induced gingival overgrowth (DIGO)
The main drugs associated with GO can be divided into three categories such 
as anticonvulsants, calcium channel blockers, and immunosuppressants. Few 
isolated incidences of GO associated with antibiotics and sulphonamides were also 
reported. Though these drugs have different pharmacologic effect and targets, 
all of them seem to act similarly on the gingival connective tissue as a secondary 
target, leading to common clinical and histopathological changes. The gingival 
overgrowth (GO) is consequent to the alteration of the host tissue response, result-
ing in an increase in collagen synthesis and cellular changes within the connective 
tissue. The prevalence of gingival overgrowth varies with different medications, 
with a reported rate of 50% for phenytoin (anticonvulsant), 25–30% for cyclospo-
rine (immunosuppressant), 5–20% for nifedipine and 3% for amlodipine (CCBs) 
[2]. The drug associated gingival overgrowth is three times more prevalent among 
men and can be attributed to the effect of testosterone on fibroblast proliferation 
and collagen stimulus [3].
The GO appears normally within 1–3 months after administration of these 
medications (Table 1). The gingival enlargement may appear inflamed or more 
fibrotic depending on the degree of inflammation. Normally the GO is confined 
to the attached gingiva which might occasionally extend coronally. The enlarged 
gingiva produces esthetic changes and its clinical symptoms include tenderness, 
bleeding, interference with speech, dental occlusion problems, and enhanced 
susceptibility to periodontal diseases [4–6].
Histologically, the drug-induced gingival overgrowth is indistinguishable from 
other types of gingival enlargement. The enlargement of the gingival tissue occurs 
as a result of accumulation of extracellular matrix (ECM), although the pathogen-
esis remains multifactorial. Age, genetic predisposition, pharmacokinetic variables, 
drug-induced alterations in gingival connective tissue homeostasis, inflammatory 
changes, drug-induced action on growth factors, etc. are some of the factors that 
influences the occurrence and severity of the gingival overgrowth.
Genetic factors are important in the pathogenesis of drug associated gingival 
overgrowth. The drugs are metabolized by cytochrome p450 enzymes, which are 
characterized by high genetic variability. Research on genes responsible for HLA 
leukocyte antigen coding confirmed the theory of HLA-DR2 antigen influence, 
which is found much more commonly in patients with moderate or severe drug-
induced gingival overgrowth than HLA-DR1 [7]. The drug variables such as dosage, 
duration of therapy and concentration of drug in plasma and local fluids, like 
gingival crevicular fluid and saliva, play an important role in DIGO [8].
2.1 Pathogenesis of DIGO
The exact mechanism behind the pathogenesis of drug-induced gingival over-
growth is not yet fully understood. Each medication has got separate impacts on 
the range of cytokines and growth factors involved in connective tissue metabo-
lism. Studies revealed that the molecular markers and clinical features of gingival 
overgrowth differ depending on the drugs. The cytokine and growth factor balances 
are altered in tissues with GO, including connective tissue growth factor (CTGF), 
a member of the interesting CCN (cysteine-rich angiogenic protein 61) family of 
factors [3, 9, 10].
Cytokine dependent alterations in extracellular matrix metabolism appear to be 
of functional importance to gingival overgrowth. Abnormal differentiation of cells, 
resulting in accumulation of fibroblasts with a pathologic range of proliferative 
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and synthetic phenotypes, could result from deregulated cytokines. The unique 
metabolic aspects of gingival extracellular matrix metabolism; and a greater under-
standing of interactions between and among medications, the innate and acquired 
immune response, cytokines and growth factors, and gingival epithelial and con-
nective tissue cells providing more detailed molecular and mechanistic information 
need to be elucidated [3, 11].
2.2 Histological features
Histologically, slight to moderate hyperkeratosis, thickening of the spinous layer, 
fibrosis of underlying connective tissue with fibroblastic proliferation, increase 
in the number of capillaries with slight chronic perivascular inflammation is seen. 
Excessive accumulation of extracellular matrix like collagen with varying amounts 
of inflammatory infiltrates, predominantly plasma cells are seen. Fibroblastic 
proliferation may not be evident. Plasma cells are the principal type of infiltrating 
Drugs/groups Incidence/prevalence References
Anticonvulsants
Phenytoin 13% [17]
50.3% [18]
57% [19]
40% [20]
50–60% [21]
53% [22]
Sodium valproate Rare [22]
Vigabatrin Rare [23, 24]
Carbamazepine None [22]
Immunosuppressants
Cyclosporines 10–85% [25]
30% [26]
8–70% [27]
25–81% [8]
22.4% [28]
Tacrolimus 14.1% [28]
Calcium channel blockers
Nifedipine 6.3% [29]
50.8% [30]
83% [31]
Diltiazem 20% [31]
Verapamil 4–19% [32, 33]
Amlodipine 3% [34, 35]
Felodipine Rare [36]
Table 1. 
Medications causing drug induced gingival overgrowth (DIGO).
Oral Diseases
4
inflammatory cell. Parakeratinized epithelium of variable thickness covers the con-
nective tissue stroma. The epithelial ridges may penetrate deep into the connective 
with columns of interspersed collagen fibers [12].
2.3 Management of drug induced DIGO
The management of medication induced gingival overgrowth depends on the 
degree of progression of the disease. Withdrawal or substitution of medication is 
one of the methods that might resolve the gingival overgrowth. However, not all 
patients respond to this mode of treatment especially those with long standing 
gingival enlargement. Professional debridement with scaling and root planning 
as needed has been shown to offer some remission of the gingival overgrowth in 
patients. Since the anterior labial gingiva is frequently involved, surgery is com-
monly performed for esthetic reasons. The classical surgical approach has been 
the external bevel gingivectomy. However, a total or partial internal gingivectomy 
approach has been suggested as an alternative. This approach has the benefit of 
limiting the large denuded connective tissue wound and thereby minimizing 
postoperative pain and bleeding [13].
The surgical methods include traditional scalpel gingivectomy and periodontal 
flap surgery. Electrocautery may be used in difficult cases, children, or where the 
gingiva is fragile and likely to bleed. Excision using laser provides a superior inci-
sion margin and improved wound healing due to a coagulated layer along the inci-
sion, as well as a reduced incidence of scarring. CO2 laser is very effective in surgery 
of soft tissues with high water content like the gingiva. Blood vessels up to a diam-
eter of 0.5 mm can be sealed effectively and provides a dry field for better visibility 
of the surgical field. A laser is preferred over the scalpel as it has strong bactericidal 
and hemostatic effects [14, 15]. A combined non-surgical and surgical therapy 
with drug substitution is the most common treatment approach in the manage-
ment of medication induced gingival overgrowth [16]. In most cases, conservative 
methods such as professional oral hygiene maintenance, topical anti-inflammatory 
and antibacterial drugs and a meticulous oral hygiene measures by the patient. 
Surgical excision is used in cases of where the gingival overgrowth interferes with 
food intake, causing difficulties in speech and maintaining oral hygiene. Surgical 
excision is more reliable as it eliminates the hyperplastic tissue and promotes plaque 
control as well as improves the esthetics.
2.4 Phenytoin
Phenytoin is an anticonvulsant prescribed for the control of epilepsy and neu-
ralgias. In the present day, phenytoin is not usually prescribed as a first line drug 
for the management of epilepsy due to the availability of a wide range of newer, 
more effective anticonvulsant drugs with fewer side effects. The prevalence of 
drug-induced gingival overgrowth in patients taking phenytoin is reportedly 
between 15% and 60% [17]. Phenytoin, or its metabolites, probably acts directly 
on high activity fibroblasts leading to the high levels of production of collagen 
in the presence of inflammation. This results in gingival enlargement, charac-
teristically originating principally from the interdental papillae (Figure 1). The 
amount or degree of severity of the overgrowth is not related to the dose of the 
drug. Presence of plaque and gingival inflammation, serum concentrations of  
the drug are factors which increases the risk of phenytoin-induced gingival 
overgrowth [37].
The management of this overgrowth is based on obtaining optimal control of 
plaque. Where the enlargement is unsightly and disfiguring, or even interfering 
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with chewing, the over-growths should be removed. Gingivectomy appears to be 
the simplest and best way of achieving good gingival contour as a post-operative 
result. But optimal plaque control post-operatively is the most important deter-
minant of success. Recent research work suggests that the use of chlorhexidine, 
especially brushing daily using the gel, can be of valuable assistance in controlling 
plaque and hence in controlling the overgrowths in the post-surgical phase.
2.5 Cyclosporin
Cyclosporin (CsA) is a cyclic polypeptide with potent immunosuppressive 
activity used widely to prevent organ transplant rejection and also in the treatment 
of autoimmune diseases [38, 39]. CsA selectively suppresses helper T-cell function 
and modulates the network of inflammatory cytokines. However, cyclosporin is 
associated with several untoward effects like nephrotoxicity, hepatotoxicity, hirsut-
ism and gingival overgrowth [40, 41]. Gingival overgrowth is one of the common 
side effects of CsA treatment, observed in 13–81% of the patients [6, 39]. The 
prevalence of gingival overgrowth associated with CsA averages around 30%, with 
reported rates ranging from 10 to 85% [25]. Studies have shown certain degree of 
association between GO and potential risk factors, such as age, genetic susceptibil-
ity, pharmacokinetic variables, plaque-related inflammation and immunological 
changes [42–44]. Epidemiological studies have reported wide variation of its 
occurrence and it accounts for more than 70% of the transplant recipients [4, 45]. 
The severity of gingival overgrowth is often associated with its prolonged use and 
further influenced by bacterial plaque and local irritants (Figure 2) [46]. The use 
of other medication, such as calcium channel blockers along with CsA increases the 
prevalence of gingival overgrowth and subsequently the risks [11]. The condition 
can interfere with the mastication, speech and oral hygiene maintenance and has a 
psychological impact in the affected individual [5].
The most prominent pathologic manifestation of the gingival overgrowth is an 
excessive accumulation of extracellular matrix, predominantly type I collagen. Many 
studies have shown increased transcriptional and translational levels of type I collagen 
in both tissue and fibroblast cultures derived from CsA-induced gingival overgrowth 
[9, 10, 47]. Though the exact mechanism is not clearly understood, studies also have 
shown increased expression of specific cytokines, especially transforming growth 
factor-beta (TGF-β), in drug-induced gingival overgrowth. This suggests that TGF-β, 
an inflammatory mediator that regulates cell proliferation and differentiation, plays a 
role in enlarging the extracellular matrix in hyperplastic gingival tissue [48].
Figure 1. 
A case of phenytoin induced gingival overgrowth.
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The management of cyclosporin associated gingival overgrowth includes 
removal of local irritants and plaque and maintenance of adequate oral 
hygiene. Invasive procedures, such as gingivectomy is done in severe cases 
[49]. Currently the use of antibiotics has shown reduction in the GO associated 
with the drug usage. Azithromycin, a semi synthetic antibiotic, derived from 
the macrolide erythromycin has shown reduction in gingival overgrowth [50]. 
Roxithromycin, a macrolide antibiotic with similar characteristics of azithro-
mycin, is also found to be effective in the reduction of gingival overgrowth in 
renal transplant recipients on CsA [25]. Gingival overgrowth can be prevented 
by intensive plaque-control practices including meticulous brushing, although 
critically ill patients receiving CsA may not be the ideal candidates for such 
intensive procedures. A combination of chlorhexidine or normal saline mouth 
rinses and mechanical cleaning was found to be effective in controlling the 
management of such patients [51, 52].
2.6 Calcium channel blockers
Drugs including diuretics, alpha and beta blockers, angiotensin converting 
enzyme inhibitors, angiotensin II type 1 receptor blockers and calcium channel 
blockers (CCBs) have been used to manage hypertension [53]. They are adminis-
tered either alone or in combination, depending on the needs of the patient. The 
calcium channel blockers are the most frequently prescribed antihypertensive 
agents which is comprised of two subclasses, dihydropyridines and non-dihy-
dropyridines. Although their mechanism of action is the same, they have varied 
pharmacological effects. While the dihydropyridines are potent vasodilators, the 
non-dihydropyridines produce more negative inotropic effects. The dihydropyri-
dines such as nifedipine, amlodipine and felodipine are significantly associated with 
gingival overgrowth. The non-dihydropyridines such as diltiazem and verapamil 
are less commonly associated with gingival enlargement [54].
2.6.1 Nifedipine
Nifedipine, a drug that belongs to a pharmacological agent group known as 
calcium channel blocker was introduced in 1972 and has been used widely in the 
management of hypertension and angina pectoris. Lederman et al. [55] was the first 
to describe nifedipine-induced gingival overgrowth in patients treated with this 
drug. The prevalence of nifedipine-induced gingival overgrowth is between 30 and 
50% and was found to be 3 times likely to develop in males [29]. The overgrowth 
Figure 2. 
A case of cyclosporin A induced gingival overgrowth.
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appears 1–9 months after administration of the drug and the most common sites 
affected included the labial anterior gingiva of both jaws [56, 57]. A multifactorial 
pathogenesis has been suggested including environmental, genetic, immunologi-
cal and inflammatory factors [58]. The interdental papilla becomes more grossly 
enlarged followed by the marginal and the attached gingiva (Figure 3). Presence 
of gingival periodontal disease and dental plaque has been reported as significant 
risk factors in the development of gingival enlargement. Several hypotheses have 
been put forward to explain the phenomena of the gingival overgrowth. The 
interaction between nifedipine and gingival fibroblasts contain increased sulfated 
mucopolysaccharides which are precursors of ground substance, leading to the 
overproduction of collagen and extracellular ground substance [59]. A genetically 
specific predetermined subpopulations of fibroblasts are identified which are sensi-
tive to nifedipine and cause an increase in the production of collagen [60]. The dose 
of nifedipine is important and it was found that its presence in gingival crevicular 
fluid is 15–316 times higher than plasma. The higher concentration of nifedipine in 
the gingival crevicular fluid could increase the severity of gingival enlargement.
2.6.2 Amlodipine
Amlodipine is a third-generation dihydropyridine calcium channel block-
ers (CCB) that is used in the management of both hypertension and angina. 
The prevalence of gingival overgrowth associated with amlodipine is between 
1.7% and 3.3% [35]. Though the etiopathology of this adverse reaction is not 
clearly understood, mechanisms such as inflammatory and non-inflammatory 
pathways have already been hypothesized. The non-inflammatory mechanisms 
involves a defective collagenase activity due to decreased uptake of folic acid, 
blockage of aldosterone synthesis in the adrenal cortex and consequent increase 
in Adrenocorticotropic hormone level, and up-regulation of keratinocyte 
growth factor [61]. The inflammatory pathway develops as a result of direct 
toxic effects of concentrated drug in gingival crevicular fluid and bacterial 
plaques leading to the up-regulation of several cytokine factors such as trans-
forming growth factor-beta (TGF-β) [62].
The gingival overgrowth normally begins at the interdental papillae and is 
more frequently found in the anterior segment of the labial surfaces. Subsequently 
gingival lobulations that develop might appear as inflamed or fibrotic in nature 
depending on the degree of contributing factors (Figure 4). Normally the fibrotic 
enlargement is confined to the attached gingiva which might advance coronally and 
Figure 3. 
A case of nifedipine induced gingival overgrowth.
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interfere with esthetics, mastication, or speech [63]. Management of amlodipine 
induced gingival overgrowth includes substitution of the drug and controlling the 
other risk factors with meticulous mechanical and chemical plaque control. Surgical 
management of the overgrowth is advised in cases to accomplish an esthetic and 
functional outcome [64].
2.6.3 Verapamil
Verapamil is an effective preventive agent in both episodic and chronic clus-
ter headache. Gingival overgrowth is an infrequent adverse effect of Verapamil 
and a prevalence rate of around 4.2% has been reported [33]. Histologically, 
verapamil induced gingival enlargement shows a highly vascular connective 
tissue, acanthotic and thickened epithelium with long rete pegs containing 
dyskeratotic pearls, and varying amounts of subepithelial inflammatory infil-
trate which is similar to other group of drugs [65]. The histological appearance 
is similar to that caused by phenytoin, cyclosporin, and other calcium channel 
antagonists. Discontinuation of the drug usually results in complete regression 
of the gingival overgrowth.
3. Other effects of medications on periodontal tissues
3.1 Minocycline
Minocycline, a semi-synthetic broad-spectrum antimicrobial agent, is mainly 
used for the treatment of acne, chronic respiratory diseases, and rheumatoid 
arthritis. It is lipid soluble and therefore can easily penetrate into body fluids, 
such as saliva and gingival crevicular fluid, and into various body tissues includ-
ing bone and soft tissues [66]. Minocycline-induced pigmentation of oral mucous 
membranes including the buccal mucosa, gingiva, palatal area, lips and tongue has 
been reported [67–69]. The pathophysiology of minocycline staining is not clearly 
understood. It has been suggested that either a minocycline-metabolite complex or 
melanin, iron and calcium-containing granules are the source of the pigment [70]. 
The pigmentation of oral soft tissues appears as distinctive blue-gray or brown in 
color and occurs as a result of pigmented black bone visible through the thin over-
lying mucosa without any actual involvement of the soft tissue itself (Figure 5) 
[71]. The pigmentation appears to be related to the duration of minocycline 
Figure 4. 
A case of gingival overgrowth in a patient on amlodipine.
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therapy or the cumulative dose, and resolves once the drug is discontinued [69, 72]. 
Intraoral pigmentation can be managed with lasers [71].
3.2 Oral contraceptives
A higher prevalence of gingival inflammation, loss of attachment and gingival 
enlargement in woman taking hormone based oral contraceptives [73, 74]. The gin-
gival inflammation seems to be associated to high concentrations of sex hormones 
present in oral contraceptives (Figure 6) [75]. Oral contraceptives (OCs) enhance 
periodontal breakdown by reducing the resistance to dental plaque and can induce 
gingival enlargement in otherwise healthy females [76, 77]. Oral contraceptives 
have pronounced effects on gingival microvasculature and it has been shown that 
human gingiva contains receptors for progesterone and estrogen. The dosage and 
duration of intake are the possible factors which influence the effect of oral contra-
ceptives on the periodontal condition. A continued exposure of oral contraceptives 
for longer duration results in higher risk of periodontal disease development due to 
increased production of pro-inflammatory cytokines and prostaglandins as a result 
of elevated levels of the hormones [78, 79]. However, the currently used combined 
oral contraceptives showed little influence on the periodontal health, possibly 
related to their lower concentration of progesterone and estrogen compared to the 
earlier formulations [74, 80]. A critical review supports the conclusion that there 
is no impact of modern oral contraceptives on the periodontal and gingival tissues. 
Figure 5. 
Discoloration of the gingiva and teeth in a patient on minocycline therapy.
Figure 6. 
Gingival changes in a patient on oral contraceptives.
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Hence, it is concluded that oral contraceptives can no longer be considered to 
constitute a risk factor for gingivitis or periodontitis [81].
3.3 Bisphosphonates
Bisphosphonates are used widely in the management of primary and meta-
static bone cancer, as well as osteoporosis. Bisphosphonates improve bone 
mineral density, reduce fracture risk, and reduce hypercalcemia of malignancy. 
Incidents of osteonecrosis of the jaw have been reported in people on bisphos-
phonates and undergoing invasive dental treatment procedures, including tooth 
extractions, dental implants, and surgical and nonsurgical periodontal treat-
ment [82]. The risk for bisphosphonate-induced osteonecrosis may be influ-
enced by the route of administration of the drug, the potency and the duration 
of use. Jaw osteonecrosis appears more associated with the intravenous use of 
bisphosphonates. A review showed that 94% of the published cases of osteo-
necrosis correlated with administration of intravenous, nitrogen-containing 
bisphosphonates [83].
Bisphosphonates inhibit bone resorption by acting on osteoclasts to reduce their 
activity or to increase the rate of apoptosis [84]. The inhibitory effect on osteoclast 
function, bone formation coupled with resorption results in an overall reduction 
in the rate of bone remodeling [85]. Moreover, bisphosphonates may antagonize 
the action of several matrix metalloproteinase involved in breakdown of structural 
components of periodontal connective tissue [86]. In view of the antiresorptive 
properties of bisphosphonates and the ability to inhibit cytokines of periodontal 
tissue destruction, there has been interest in the possible use of bisphosphonates as 
an adjunct to scaling and root planning in the management of periodontitis [87, 88]. 
Although bisphosphonates claim its effectiveness in controlling periodontal destruc-
tion, clinical use warrants further evidence. A systematic review concluded that 
bisphosphonates may be used topically as an adjunct to scaling and root planing [89].
3.4 Statins
Statins, or inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMG-CoA reductase), are a group of drugs, used mainly to treat hyperlipid-
emia. In addition to their cholesterol lowering properties they also have strong 
anti-inflammatory properties and may stimulate bone growth [90]. Statins 
have anabolic effects on the bone by augmenting bone morphogenetic protein-2 
expression and thereby contributing towards the differentiation and activity of 
osteoblasts [91]. Due to their activity on bone formation statins have been con-
sidered as potential agents in improving periodontal treatment outcomes [92]. 
Limited data is available on the impact of stains on periodontal tissues suggesting 
a reduction in periodontal destruction and tooth loss [93]. Experimental studies 
on rats support the potential protective effect of statins on periodontal bone loss. 
Although these basic data are interesting, further research could extrapolate the 
use of statins as a potential adjunctive therapeutic agent in periodontal disease 
and bone regeneration.
3.5 Anti-platelet drugs
Anti-platelet drugs are widely used for the treatment of established cardiovascu-
lar disease, the prevention of atherothrombotic events and the treatment of myo-
cardial infarction. The most commonly prescribed antiplatelets drugs are aspirin 
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and clopidogrel which are often used in combination. Both of these drugs have been 
reported to cause increased gingival bleeding. Patients on these medications carry 
a risk of an increased tendency to bleeding during or following periodontal surgery 
and this risk is far greater when the drugs are used in combination [94].
4. Conclusion
Several systemic factors are known to contribute to periodontal diseases or 
conditions and among those are the intake of drugs. The gingival overgrowth 
associated with medications occur as a side effect of systemic medications. These 
medications include the anti-seizure drug phenytoin, the immune suppressor 
cyclosporin A, and certain anti-hypertensive dihydropyridine calcium-channel-
blockers, most notably nifedipine. It is crucial that health professionals under-
stand the complications that medications can have on the oral health of their 
patients. In order to properly diagnose and treat patients, a complete medical 
history including prescription medications, over the counter drugs and dietary 
supplements must be recorded which will enable the healthcare team to identify 
the causative agents.
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